Immune Microenvironment and Novel Immunotherapeutic Strategies in Medulloblastoma

DOI

10.2991/978-94-6463-910-0_18How to use a DOI?

Keywords

Medulloblastoma; Tumor Immune Microenvironment; T cell; Immunotherapy; Immune Checkpoint Inhibitor

Abstract

Medulloblastoma (MB) is a primary malignant tumor of the central nervous system (CNS) commonly found in children, with an approximate 5-year overall survival (OS) rate of 70%. Currently, the standard treatment regimen for MB involves surgical resection of the tumor combined with postoperative radiotherapy and chemotherapy. Despite the fact that this treatment regimen has notably extended the survival time of patients, the associated adverse reactions impact the prognosis of life of patients, and the recurrence rate after treatment remains relatively high. The tumor microenvironment (TME), which includes tumor cells, non-tumor cells, extracellular matrix, and various signaling molecules, refers to the biological environment in which tumor cells reside. Immune checkpoint molecules are negative immunoregulatory molecules located on the surface of tumor cells. They directly bind to the corresponding receptors on the surface of T cells, which can inhibit the activation, proliferation, cytokine secretion, and cytotoxic reactions of T cells, and subsequently reduce the attack of the immune system on tumor cells. In recent years, immune checkpoint inhibitors (ICIs) have emerged as a vital approach in the immunotherapy of malignant tumors. These medications can impede the binding of immune checkpoint molecules to their ligands, relieve the inhibitory effect on immune cells, and restore the anti-tumor activity of immune cells. This article presents an overview of the immune microenvironment of medulloblastoma and discusses the potential application of immune checkpoint inhibitors, offering a certain reference for the immunotherapy of medulloblastoma.

Copyright

© 2025 The Author(s)

Open Access

Open Access This chapter is licensed under the terms of the Creative Commons Attribution-NonCommercial 4.0 International License (http://creativecommons.org/licenses/by-nc/4.0/), which permits any noncommercial use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license and indicate if changes were made.

Download article (PDF)

TY  - CONF
AU  - Yuxuan Zeng
PY  - 2025
DA  - 2025/12/15
TI  - Immune Microenvironment and Novel Immunotherapeutic Strategies in Medulloblastoma
BT  - Proceedings of the 2025 2nd International Symposium on Agricultural Engineering and Biology (ISAEB 2025)
PB  - Atlantis Press
SP  - 167
EP  - 175
SN  - 2468-5747
UR  - https://doi.org/10.2991/978-94-6463-910-0_18
DO  - 10.2991/978-94-6463-910-0_18
ID  - Zeng2025
ER  -